Anna Moore - 08 Jul 2021 Form 3 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role
10%+ Owner
Signature
/s/ Thomas A. Fitzgerald, Attorney-in-Fact
Issuer symbol
RNAZ
Transactions as of
08 Jul 2021
Net transactions value
$0
Form type
3
Filing time
08 Jul 2021, 21:52:36 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RNAZ Common Stock 1,552,785 08 Jul 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RNAZ Stock Option (Right to Buy) 08 Jul 2021 Common Stock 60,655 $0.0910 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the Stock Options shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (January 1, 2020), provided that the Optionee continues to have a Service Relationship with the Company at such time. Thereafter, the remaining seventy-five percent (75%) of the Stock Options shall vest and become exercisable in 36 equal monthly installments on the last day of each month beginning with the month of the first anniversary of the Vesting Commencement Date, provided the Optionee continues to have a Service Relationship with the Company on each vesting date.

Remarks:

Exhibit 24: Power of Attorney